hero section gradient
16 handpicked stocks

HBM4 Memory: Balancing Supply Stability vs Market Risk

Samsung is set to begin mass production of its HBM4 memory chips for Nvidia, a key move in the AI hardware race. This development signals a broader investment opportunity in the semiconductor supply chain, as the demand for advanced AI components accelerates.

Author avatar

Han Tan | Market Analyst

Published on January 26

Your Basket's Financial Footprint

This basket's total market capitalisation is 7,359,913.8793 and is heavily anchored by a few very large‑cap positions, suggesting a large‑cap, lower‑volatility profile. Such concentration tends to produce more stable, market‑tracking behaviour than small‑cap or speculative baskets.

Key Takeaways for Investors:
  • Performance and risk: Large‑cap dominance generally implies lower volatility and closer tracking to broad market movements.
  • Consider as core holding: Suited for a foundational allocation rather than a speculative, high‑beta trade.
  • Expect steady, long‑term appreciation potential; do not expect rapid, short‑term explosive gains.
Total Market Cap
  • NVDA: $4.56T

  • MU: $449.81B

  • TSM: $1.45T

  • Other

About This Group of Stocks

1

Our Expert Thinking

Samsung's mass production of HBM4 memory chips for Nvidia represents a pivotal moment in the AI hardware race. This development signals a stabilisation of the supply chain for High-Bandwidth Memory, creating opportunities across the entire semiconductor ecosystem from chip designers to data centre infrastructure providers.

2

What You Need to Know

This group focuses on companies essential to the AI memory supply chain - a rapidly growing market driven by insatiable demand for advanced AI components. These stocks represent exposure to a cyclical but long-term theme as the world builds out AI infrastructure at unprecedented scale.

3

Why These Stocks

Each company was handpicked by professional analysts based on their critical role in the HBM and AI hardware ecosystem. From memory manufacturers to foundries to equipment makers, these stocks represent the intricate network powering next-generation artificial intelligence accelerators.

Why You'll Want to Watch These Stocks

🚀

Supply Chain Breakthrough

Samsung's HBM4 mass production creates a more stable and competitive memory supply chain, potentially accelerating AI hardware deployment across the industry.

🏗️

Infrastructure Build-Out

The AI revolution requires massive infrastructure investment, from advanced memory chips to data centres, creating opportunities throughout the supply chain.

Professional Selection

These companies were carefully chosen by expert analysts for their critical roles in powering next-generation AI accelerators and infrastructure.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Beverage Stocks: What's Next After Coca-Cola's Pivot

Beverage Stocks: What's Next After Coca-Cola's Pivot

Coca-Cola is discontinuing its historic Minute Maid frozen products to focus on faster-growing beverage categories. This strategic shift highlights a broader investment opportunity in companies leading the market's transition toward healthier, more convenient, and functional drinks.

Factory Automation Stocks | Rising Labor Costs Trend

Factory Automation Stocks | Rising Labor Costs Trend

Volkswagen's recent agreement with the UAW signals a new era of rising labor costs for foreign automakers in the U.S. This theme focuses on companies poised to benefit as the industry increases investment in factory automation and robotics to enhance productivity.

Blood Thinner Breakthrough Explained | Market Overview

Blood Thinner Breakthrough Explained | Market Overview

Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.

Frequently Asked Questions